Kamada Stock Price, News & Analysis (NASDAQ:KMDA)

$5.65 0.10 (1.80 %)
(As of 01/18/2018 11:07 AM ET)
Previous Close$5.55
Today's Range$5.50 - $5.65
52-Week Range$3.75 - $8.61
Volume31,700 shs
Average Volume32,355 shs
Market Capitalization$223.82 million
P/E Ratio-141.21
Dividend YieldN/A
Beta1.03

About Kamada (NASDAQ:KMDA)

Kamada logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Debt-to-Equity Ratio0.02%
Current Ratio3.71%
Quick Ratio2.73%

Price-To-Earnings

Trailing P/E Ratio-141.214696325919
Forward P/E Ratio70.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$77.49 million
Price / Sales2.94
Cash FlowN/A
Price / CashN/A
Book Value$1.83 per share
Price / Book3.09

Profitability

Trailing EPS($0.04)
Net Income$-6,730,000.00
Net Margins-1.27%
Return on Equity-1.64%
Return on Assets-1.14%

Miscellaneous

Employees377
Outstanding Shares40,330,000

Kamada (NASDAQ:KMDA) Frequently Asked Questions

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd (NASDAQ:KMDA) announced its earnings results on Monday, November, 13th. The biotechnology company reported ($0.01) EPS for the quarter. Kamada had a negative net margin of 1.27% and a negative return on equity of 1.64%. View Kamada's Earnings History.

When will Kamada make its next earnings announcement?

Kamada is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Kamada.

Where is Kamada's stock going? Where will Kamada's stock price be in 2018?

2 equities research analysts have issued twelve-month price objectives for Kamada's shares. Their predictions range from $7.00 to $10.00. On average, they anticipate Kamada's stock price to reach $8.50 in the next twelve months. View Analyst Ratings for Kamada.

Who are some of Kamada's key competitors?

Who are Kamada's key executives?

Kamada's management team includes the folowing people:

  • Leon Yehuda Recanati, Chairman of the Board (Age 67)
  • Amir London, Chief Executive Officer (Age 46)
  • David Tsur, Deputy Chairman of the Board (Age 67)
  • Chaime Orlev, Chief Financial Officer (Age 46)
  • Ruth Wolfson, Senior Vice President - Scientific Affairs (Age 69)
  • Barak Bashari, Vice President - Operations (Age 51)
  • Shani Dotan, Vice President - Human Resources (Age 42)
  • Yael Brenner, Vice President - Quality (Age 52)
  • Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D (Age 50)
  • Eran Schenker, Vice President - Medical Director (Age 53)

Who owns Kamada stock?

Kamada's stock is owned by a variety of of retail and institutional investors. Top institutional investors include MEITAV DASH INVESTMENTS LTD (9.17%), MEITAV DASH INVESTMENTS LTD (9.17%) and BROSH CAPITAL PARTNERS L.P. (7.30%). View Institutional Ownership Trends for Kamada.

How do I buy Kamada stock?

Shares of Kamada can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of Kamada stock can currently be purchased for approximately $5.65.

How big of a company is Kamada?

Kamada has a market capitalization of $223.82 million and generates $77.49 million in revenue each year. The biotechnology company earns $-6,730,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Kamada employs 377 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 7 SAPIR STREET KIRYAT WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7414002. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (KMDA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kamada (NASDAQ:KMDA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.50$8.50$8.50$9.50
Price Target Upside: 75.26% upside75.26% upside75.26% upside32.87% upside

Kamada (NASDAQ:KMDA) Consensus Price Target History

Price Target History for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017Jefferies GroupReiterated RatingBuy$7.00N/AView Rating Details
2/7/2017HC WainwrightSet Price TargetBuy$10.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Kamada (NASDAQ:KMDA) Earnings History and Estimates Chart

Earnings by Quarter for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ KMDA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018        
11/13/2017Q3 2017($0.01)ViewN/AView Earnings Details
8/1/20176/30/2017$0.12$0.13$33.30 million$32.55 millionViewListenView Earnings Details
5/16/20173/31/2017($0.03)($0.11)$20.82 million$11.65 millionViewN/AView Earnings Details
2/6/201712/31/2016($0.04)($0.05)$27.74 million$24.26 millionViewListenView Earnings Details
11/10/20169/30/2016($0.04)($0.03)$20.32 million$19.37 millionViewN/AView Earnings Details
8/2/2016Q216($0.04)($0.04)$18.50 million$19.10 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.06)($0.06)$15.10 million$14.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05$24.53 million$25.79 millionViewN/AView Earnings Details
11/12/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.01$0.03ViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)($0.07)ViewN/AView Earnings Details
3/9/2013Q4 2012($0.03)$0.11ViewN/AView Earnings Details
2/28/2012Q4 2011($0.03)($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Kamada (NASDAQ:KMDA) Earnings Estimates

Current Year EPS Consensus Estimate: $0.08 EPS
Next Year EPS Consensus Estimate: $0.09 EPS

Dividends

Dividend History for Kamada (NASDAQ:KMDA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kamada (NASDAQ KMDA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Kamada (NASDAQ KMDA) News Headlines

Source:
DateHeadline
Zacks: Kamada Ltd (KMDA) Given $8.50 Consensus Target Price by BrokeragesZacks: Kamada Ltd (KMDA) Given $8.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - January 17 at 12:04 PM
Analyzing ChemoCentryx (CCXI) & Kamada (KMDA)Analyzing ChemoCentryx (CCXI) & Kamada (KMDA)
www.americanbankingnews.com - January 15 at 11:16 PM
Contrasting Kamada (KMDA) and Biogen (BIIB)Contrasting Kamada (KMDA) and Biogen (BIIB)
www.americanbankingnews.com - January 15 at 9:06 AM
Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant RejectionKamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
finance.yahoo.com - January 8 at 10:20 AM
Kamada (KMDA) Raised to "Hold" at ValuEngineKamada (KMDA) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - January 5 at 11:22 PM
Kamada (KMDA) & Cesca Therapeutics (KOOL) Critical AnalysisKamada (KMDA) & Cesca Therapeutics (KOOL) Critical Analysis
www.americanbankingnews.com - January 5 at 5:34 PM
Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host DiseaseKamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease
finance.yahoo.com - January 4 at 10:06 AM
 Kamada Ltd (KMDA) Given Consensus Recommendation of "Strong Buy" by Brokerages Kamada Ltd (KMDA) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 31 at 1:28 PM
ETFs with exposure to Kamada Ltd. : December 28, 2017ETFs with exposure to Kamada Ltd. : December 28, 2017
finance.yahoo.com - December 28 at 4:42 PM
 Kamada Ltd (KMDA) Given $8.50 Average Target Price by Brokerages Kamada Ltd (KMDA) Given $8.50 Average Target Price by Brokerages
www.americanbankingnews.com - December 22 at 5:23 PM
Comparing Kamada (KMDA) & Opiant Pharmaceuticals (OPNT)Comparing Kamada (KMDA) & Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - December 17 at 1:28 PM
ETFs with exposure to Kamada Ltd. : December 12, 2017ETFs with exposure to Kamada Ltd. : December 12, 2017
finance.yahoo.com - December 12 at 5:02 PM
ETFs with exposure to Kamada Ltd. : December 1, 2017ETFs with exposure to Kamada Ltd. : December 1, 2017
finance.yahoo.com - December 1 at 5:29 PM
Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 10:47 AM
 Kamada Ltd. (KMDA) Given Average Rating of "Strong Buy" by Analysts Kamada Ltd. (KMDA) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 27 at 11:26 AM
Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies InfectionKamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection
finance.yahoo.com - November 22 at 1:38 AM
 Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages
www.americanbankingnews.com - November 21 at 5:50 PM
Critical Review: Argos Therapeutics (ARGS) vs. Kamada (KMDA)Critical Review: Argos Therapeutics (ARGS) vs. Kamada (KMDA)
www.americanbankingnews.com - November 21 at 5:12 AM
Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin DeficiencyKamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency
finance.yahoo.com - November 21 at 2:07 AM
Kamada Ltd. (KMDA) Downgraded by Zacks Investment Research to Strong SellKamada Ltd. (KMDA) Downgraded by Zacks Investment Research to Strong Sell
www.americanbankingnews.com - November 19 at 8:40 AM
 Kamada Ltd. (KMDA) Receives Average Recommendation of "Strong Buy" from Analysts Kamada Ltd. (KMDA) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 17 at 8:40 AM
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017
finance.yahoo.com - November 13 at 11:29 AM
Oversold Conditions For Kamada (KMDA)Oversold Conditions For Kamada (KMDA)
www.thestreet.com - November 11 at 3:16 PM
Kamada Announces Nomination of Three New Members to its Board of DirectorsKamada Announces Nomination of Three New Members to its Board of Directors
finance.yahoo.com - November 11 at 3:16 PM
Kamada Ltd. (KMDA) Scheduled to Post Earnings on MondayKamada Ltd. (KMDA) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - November 9 at 2:01 PM
Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13
finance.yahoo.com - November 8 at 12:33 PM
Kamadas AAT fails to show significant treatment effect in type 1 diabetics in mid-stage study; shares down 4% premarketKamada's AAT fails to show significant treatment effect in type 1 diabetics in mid-stage study; shares down 4% premarket
seekingalpha.com - November 2 at 4:24 AM
Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes PatientsKamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
finance.yahoo.com - November 2 at 4:24 AM
Zacks: Brokerages Expect Kamada Ltd. (KMDA) Will Announce Quarterly Sales of $24.84 MillionZacks: Brokerages Expect Kamada Ltd. (KMDA) Will Announce Quarterly Sales of $24.84 Million
www.americanbankingnews.com - October 31 at 5:56 AM
Comparing Kamada (KMDA) & Its PeersComparing Kamada (KMDA) & Its Peers
www.americanbankingnews.com - October 30 at 11:24 PM
Contrasting Sinovac Biotech (SVA) and Kamada (KMDA)Contrasting Sinovac Biotech (SVA) and Kamada (KMDA)
www.americanbankingnews.com - October 30 at 7:40 PM
$0.01 Earnings Per Share Expected for Kamada Ltd. (KMDA) This Quarter$0.01 Earnings Per Share Expected for Kamada Ltd. (KMDA) This Quarter
www.americanbankingnews.com - October 30 at 12:56 AM
ETFs with exposure to Kamada Ltd. : October 25, 2017ETFs with exposure to Kamada Ltd. : October 25, 2017
finance.yahoo.com - October 26 at 4:31 PM
Kamada Ltd. (KMDA) Upgraded at Zacks Investment ResearchKamada Ltd. (KMDA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 26 at 12:31 AM
Kamada (KMDA) versus The Competition Head to Head ContrastKamada (KMDA) versus The Competition Head to Head Contrast
www.americanbankingnews.com - October 21 at 12:26 AM
Comparing Kamada (KMDA) & Its RivalsComparing Kamada (KMDA) & Its Rivals
www.americanbankingnews.com - October 20 at 4:26 PM
Jefferies Group LLC Reiterates "Buy" Rating for Kamada Ltd. (KMDA)Jefferies Group LLC Reiterates "Buy" Rating for Kamada Ltd. (KMDA)
www.americanbankingnews.com - October 15 at 7:06 PM
Head to Head Review: Tokai Pharmaceuticals (NVUS) versus Kamada (KMDA)Head to Head Review: Tokai Pharmaceuticals (NVUS) versus Kamada (KMDA)
www.americanbankingnews.com - October 13 at 10:32 AM
Kamada Ltd. (KMDA) Expected to Announce Quarterly Sales of $24.84 MillionKamada Ltd. (KMDA) Expected to Announce Quarterly Sales of $24.84 Million
www.americanbankingnews.com - October 12 at 1:56 AM
$0.01 EPS Expected for Kamada Ltd. (KMDA) This Quarter$0.01 EPS Expected for Kamada Ltd. (KMDA) This Quarter
www.americanbankingnews.com - October 10 at 8:20 PM
Kamada Ltd. (KMDA) Downgraded by Zacks Investment Research to "Sell"Kamada Ltd. (KMDA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - October 5 at 12:26 AM
Head-To-Head Survey: Kamada (KMDA) versus The CompetitionHead-To-Head Survey: Kamada (KMDA) versus The Competition
www.americanbankingnews.com - October 3 at 6:22 AM
Kamada Announces CFO TransitionKamada Announces CFO Transition
finance.yahoo.com - September 18 at 7:45 PM
ETFs with exposure to Kamada Ltd. : September 14, 2017ETFs with exposure to Kamada Ltd. : September 14, 2017
finance.yahoo.com - September 15 at 3:56 AM
Kamada Ltd. :KMDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017Kamada Ltd. :KMDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 6:57 AM
Analyzing Syros Pharmaceuticals (SYRS) & Kamada (KMDA)Analyzing Syros Pharmaceuticals (SYRS) & Kamada (KMDA)
www.americanbankingnews.com - September 7 at 10:03 AM
Kamada to Present Corporate Overview at Two Investor Conferences in SeptemberKamada to Present Corporate Overview at Two Investor Conferences in September
feeds.benzinga.com - September 7 at 8:20 AM
Kamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of ActionKamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action
finance.yahoo.com - September 6 at 8:42 PM
Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional SharesKamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - August 31 at 6:44 AM
Kamada (KMDA) Says FDA Issued Letter Stating that it Continues to Have Concerns and Questions About Safety and Efficacy of Inhaled AATKamada (KMDA) Says FDA Issued Letter Stating that it Continues to Have Concerns and Questions About Safety and Efficacy of Inhaled AAT
www.streetinsider.com - August 29 at 5:59 AM

SEC Filings

Kamada (NASDAQ:KMDA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kamada (NASDAQ:KMDA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kamada (NASDAQ KMDA) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.